IMDNA provides scientific, technical, manufacturing, and non-regulatory support for kit assembly, packaging, and labeling of molecular research reagents, qPCR/RT-qPCR assay components, controls, buffers, extraction reagents, immunoassay reagents, research-use kits, and related laboratory products within IMDNA's technical capabilities. Support can include bill-of-materials development, component kitting, lot traceability, fill/pack configuration, cold-storage and shipping configuration, packaging-material selection, label and artwork coordination, insert preparation, assembly instructions, packaging checks, change control, and technical documentation.
Kit assembly is more than placing individual components into a box. The assembled kit configuration should preserve component identity, quantity, storage conditions, traceability, usability, and compatibility throughout handling and distribution. IMDNA therefore approaches kit assembly as a controlled integration process linking product specifications, components, packaging materials, labeling, assembly sequence, quality checks, and shipment requirements.
Multi-component molecular and laboratory kits depend on the correct identity and quantity of every included component. For regulated IVD systems, 21 CFR §809.10 specifically emphasizes traceability of lot/control numbers and, where multiple units are intended to function together as a system, suitable uniform identification. Even for RUO products, these principles provide a strong framework for reliable kit assembly and investigation of future lot-specific questions.
Each reagent, control, buffer, tube, plate, insert, accessory, and packaging component should match the approved kit configuration.
Verify reaction count, vial count, fill volume, pack size, accessory count, and other quantitative requirements before completion of the assembled kit.
Link kit lots to the component and material lots used during assembly so manufacturing history can be reconstructed when needed.
Ensure the kit configuration supports the storage and handling requirements of its most sensitive components.
Keep product identity, lot information, quantity, storage conditions, intended-use language, and technical documents consistent across the kit.
Assembly support can range from a simple multi-vial research reagent set to a customer-branded, multi-component molecular research kit with controls, inserts, packaging, and cold-chain requirements.
Define the exact components, quantities, packaging materials, inserts, labels, accessories, and other items required for one complete kit and for each production batch.
Organize approved components by identity, lot, quantity, storage requirement, and assembly sequence before kitting begins.
Develop controlled assembly steps covering component selection, counts, placement, label checks, inserts, accessories, packaging, and final verification.
Record the reagent, control, consumable, and packaging lots used in each kit batch to support traceability and future investigation.
Support kit formats for different reaction counts, vial sizes, bulk quantities, research panel configurations, or customer requirements where feasible.
Help design split-pack or differentiated storage configurations when frozen, refrigerated, and ambient components cannot be shipped or stored together under one condition.
Where included in scope, kit controls, tubes, plates, seals, swabs, transfer devices, pipetting accessories, or other compatible laboratory items may be incorporated.
Verify kit identity, included components, counts, labels, inserts, packaging condition, and other defined release checks before shipment.
Support assembly under approved private-label or OEM configurations with customer-controlled brand elements and agreed responsibility boundaries.
IMDNA's support model connects component control with assembly, labeling, packaging, final checks, and lot-level documentation.
Packaging configuration should be selected around the physical and environmental sensitivity of the product. For molecular reagents, practical risks can include temperature excursion, repeated freeze-thaw exposure, evaporation, tube leakage, light exposure, crushing, label damage, condensation, component mixing, and shipment duration.
Tube, vial, bottle, plate, pouch, or other direct product-contact container selected for reagent compatibility, volume, closure, handling, and intended storage.
Racks, bags, cartons, inserts, dividers, trays, cushioning, or other packaging used to organize and protect components.
Frozen, refrigerated, controlled-room-temperature, dry-ice, cold-pack, or split-temperature configurations according to product stability needs.
Amber or opaque packaging, sealed pouches, desiccant, or other protective approaches where component sensitivity justifies them.
Use appropriate caps, seals, plate films, secondary containment, or other controls to reduce leakage and cross-component contamination.
Keep incompatible materials, different storage classes, fragile components, or distinct workflow steps physically organized where useful.
Select outer packaging and cushioning appropriate to normal handling, transport duration, package weight, and the sensitivity of the kit contents.
Organize kit contents so the user can identify, remove, store, and use components without unnecessary handling or confusion.
| Kit Component | Packaging Considerations | Potential IMDNA Support |
|---|---|---|
| Primer / Probe Mixes | Light sensitivity, low-volume recovery, freeze-thaw exposure, concentration identity, channel/target identification. | Tube/vial configuration, low-bind options, labeling, aliquot strategy, foil/opaque packaging where relevant. |
| PCR / RT-PCR Master Mix | Temperature stability, enzyme sensitivity, repeated freeze-thaw, fill volume, container compatibility. | Frozen/refrigerated configuration, aliquot sizing, storage text, split shipments where needed. |
| Positive / Process Controls | Target concentration, contamination risk, segregation from test reagents, stability, reconstitution where applicable. | Separate packaging, clear identification, control-specific handling information, lot traceability. |
| Extraction / Lysis Reagents | Container chemistry, leakage, larger fill volumes, temperature, transport, buffer compatibility. | Bottle/tube format, secondary containment, fill checks, storage and handling information. |
| Plates / Consumables | Physical damage, sealing, orientation, dust, compatibility with the intended workflow. | Tray/carton configuration, accessory count, protective packaging, identification. |
| Instructions / Inserts | Correct version, readability, technical consistency with the kit configuration. | Controlled insert placement, revision tracking, digital/printed documentation coordination. |
The information required on a label depends on the product's legal classification, intended use, jurisdiction, package size, and commercial role. For regulated U.S. IVDs, FDA identifies information such as product identity, intended use, manufacturer/packer/distributor information, lot/control number, reagent composition where applicable, storage instructions, preparation/reconstitution instructions, expiration or other product-usefulness information, and net quantity. These requirements should not be automatically applied to every RUO or general research reagent, but they provide useful concepts for clear product identification.
Coordinate product name, component name, target/panel designation, format, or other technical identifier used consistently across kit components.
Apply traceable lot or batch identifiers according to the defined manufacturing and kit-assembly system.
Identify reaction count, number of units, volume, concentration, or other quantity information appropriate to the product.
Communicate storage temperature, light protection, reconstitution, freeze-thaw, or other scientifically supported handling information.
Use wording appropriate to the actual product category and intended use, including RUO language when applicable.
Coordinate manufacturer, packer, distributor, private-label, or customer-brand information according to the agreed role and applicable requirements.
Coordinate technical warnings, precautions, chemical hazard communication, or handling statements where supported and applicable.
Keep current approved label artwork distinguishable from drafts and superseded versions through controlled identifiers and revision records.
Where physical label space is limited, coordinate a practical hierarchy between immediate-container information and outer-package or insert content subject to applicable requirements.
IMDNA can help translate the approved product specification into a practical manufacturing label and packaging layout.
The customer or responsible product owner should approve claims and customer-facing labeling elements within its responsibility before production.
For IVD products genuinely in the laboratory research phase of development, 21 CFR §809.10(c)(2)(i) requires the prominently placed statement “For Research Use Only. Not for use in diagnostic procedures.” FDA's RUO guidance emphasizes that RUO labeling and distribution practices should be consistent with the manufacturer's actual intended use. IMDNA therefore treats RUO status as an intended-use framework, not simply a label phrase applied to any product.
Keep label, insert, website, marketing, and technical language consistent with research use when the product is appropriately positioned as RUO.
Avoid representing an RUO product as FDA-cleared, approved, or intended for clinical diagnostic decision-making unless the required regulatory status has independently been established.
Research-use handling and assay instructions can still be scientifically detailed while remaining consistent with the actual intended use.
Customer branding does not change the underlying intended-use responsibility; private-label RUO products should remain consistently research focused.
IMDNA can support technical consistency, but customer commercial claims and jurisdiction-specific legal review remain the product owner's responsibility.
Maintain controlled copies of labels and inserts used with defined product and manufacturing lots.
Packaging and label claims should be supported by product knowledge. CLSI EP25 provides a consensus framework for establishing or verifying shelf-life and in-use stability of IVD reagents, calibrators, and controls. For IMDNA research reagents, similar study principles can be used where appropriate to build scientifically supported storage and handling information without implying formal IVD validation unless that framework applies.
Support time-point planning, storage conditions, functional testing, control materials, acceptance criteria organization, and technical review for defined stability studies.
Evaluate stability after opening, thawing, reconstitution, repeated access, or other realistic laboratory handling where relevant.
Assess whether repeated freeze-thaw cycles materially alter qPCR, immunoassay, control, or other reagent performance.
Support studies of representative temperature or shipping stress where scientifically justified for the product and distribution model.
Evaluate whether the selected vial, tube, cap, seal, plate, or other container affects recovery, stability, leakage, adsorption, or functional performance.
Coordinate storage and use-period wording with available product evidence rather than assigning unsupported conditions or dates.
Traceability is particularly important in multi-component kits because future technical investigations may require connecting the kit lot to individual reagent and packaging lots.
Assign a traceable kit-level identifier according to the defined manufacturing system.
Record which reagent, control, buffer, consumable, label, or other defined critical lots were used in the kit batch.
Capture kit quantities, components, operators, dates, checks, labels, inserts, and exceptions during assembly.
Link the applied label and insert revision to the corresponding product or kit lot.
Document packaging configuration, storage class, shipping condition, and other defined packaging attributes.
Document missing components, incorrect labels, damaged packaging, count discrepancies, or other assembly exceptions and how they were resolved.
Changes to packaging or labeling can affect product protection, user handling, traceability, claims, or compliance. A controlled change process helps distinguish simple artwork revisions from changes that may require stability, compatibility, technical, or regulatory assessment.
| Change | Potential Technical Impact | Possible Support |
|---|---|---|
| Primary container change | Adsorption, leakage, evaporation, light exposure, closure integrity, volume recovery, stability. | Compatibility review, functional comparison, stability/hold study support. |
| Secondary package change | Transport protection, temperature retention, component organization, user workflow. | Packaging comparison, shipping configuration review, assembly update. |
| Storage-condition change | Product stability, shipping, customer handling, shelf life. | Stability-study planning, evidence review, label update support. |
| Label artwork change | Product identity, claims, readability, traceability, revision control. | Artwork control, proof review, approved-copy coordination. |
| Kit component change | Compatibility, assay workflow, performance, instructions, BOM, traceability. | Technical impact review, bridging/QC studies, BOM and insert revision. |
| Pack-size change | Fill volume, number of uses, freeze-thaw exposure, storage and handling. | Fill strategy, packaging configuration, label and handling update. |
Regulatory requirements depend on product classification, intended use, commercial claims, and the role of each organization. FDA's Quality Management System Regulation (QMSR) became effective February 2, 2026 for applicable medical-device manufacturers and incorporates ISO 13485:2016 by reference. FDA also regulates firms that manufacture, repackage, relabel, and/or import medical devices sold in the United States. These frameworks should not be assumed to apply to every IMDNA research kit, but they are relevant when a product falls within the regulated-device or IVD framework.
A kit box, private-label arrangement, or label design does not determine regulatory classification; the actual product and intended use do.
For applicable regulated devices, packaging and labeling controls are part of the manufacturer's quality-system responsibilities.
Regulated-device labeling systems are expected to prevent mix-ups and ensure that the correct approved labeling is issued and used.
Applicable quality systems may require controlled records linking components, labels, packaging, and manufacturing history.
QMSR applies to applicable finished medical-device manufacturers; applicability to a specific IMDNA/customer product must be determined from the product and commercial role.
Kit assembly or labeling by IMDNA does not itself establish FDA clearance, approval, registration, listing, certification, or other market authorization.
IMDNA provides scientific, technical, kit-assembly, packaging, labeling, manufacturing, documentation, QC, private-label/OEM, technology-transfer, and non-regulatory support based on the needs of each project. Support may include assistance with bill-of-materials development, component staging, kit assembly, pack-size configuration, lot traceability, packaging selection, storage/shipping configuration, label and artwork coordination, inserts, assembly records, packaging checks, stability-support studies, change control, and ongoing technical support.
Where appropriate, IMDNA may assemble and package research-use products under IMDNA branding, customer branding, co-branding, customer-controlled specifications, bulk/component supply, or other agreed configurations.
IMDNA is not a regulatory, licensing, accreditation, certification, legal, trademark, governmental, or inspecting authority. IMDNA does not independently determine that customer claims, labels, brand names, artwork, intended uses, registrations, market authorizations, translations, warnings, or commercial practices satisfy every applicable requirement.
The customer or responsible product owner is responsible for determining the product's regulatory classification and intended use; ensuring rights to brand names, logos, trademarks, and artwork; approving final customer-facing labels, claims, and translations; determining jurisdiction-specific labeling, registration, listing, licensing, distribution, and market-authorization requirements; and obtaining qualified independent review where required.
Where IMDNA performs manufacturing, kit assembly, packaging, or labeling activities, IMDNA remains responsible for the activities assigned to it under the applicable manufacturing arrangement and quality system. Contractual allocation of work does not eliminate obligations that applicable law or regulation assigns directly to either party.
References to governmental, regulatory, standards-development, scientific, or professional organizations are provided for general informational purposes only and do not imply endorsement, approval, affiliation, certification, or sponsorship of IMDNA or its services.
The following official and consensus-standard resources support the general concepts of IVD labeling, lot traceability, RUO labeling, storage and stability claims, packaging/label controls, and device quality systems. Their formal applicability depends on the product, intended use, and regulatory classification.
Tell IMDNA about your kit components, assay or reagent, reaction count, vial sizes, storage temperatures, pack format, controls, accessories, customer branding, shipping conditions, label requirements, inserts, lot-traceability needs, and expected production volume. Our scientific and manufacturing team can help organize a practical kit-assembly and packaging program covering BOM control, component staging, assembly, packaging, labels, artwork coordination, documentation, stability support, recurring production, and scale-up.